Viking Therapeutics, Inc.

États‑Unis d’Amérique

 
Quantité totale PI 51
Rang # Quantité totale PI 27 244
Note d'activité PI 2,6/5.0    50
Rang # Activité PI 14 710
Symbole boursier
ISIN US92686J1060
Capitalisation 5,700M  (USD)
Industrie Biotechnology
Secteur Healthcare
Classe Nice dominante Services scientifiques, technolo...

Brevets

Marques

18 1
13 0
19 0
0
 
Dernier brevet 2025 - Pharmaceutical formulations and ...
Premier brevet 2016 - Conjoint therapies with inhibito...
Dernière marque 2015 - VIKING THERAPEUTICS
Première marque 2015 - VIKING THERAPEUTICS

Industrie (Classification de Nice)

Derniers inventions, produits et services

2024 Invention Compositions and methods for the treatment of metabolic and liver disorders. Disclosed herein are...
Invention Pharmaceutical compositions and methods for the treatment of metabolic and liver disorders. Discl...
2023 Invention Oral dosage forms for the treatment of liver disorders and methods of preparing the same. The pre...
Invention Crystalline forms and methods of producing crystalline forms of a compound. Disclosed herein are ...
Invention Compositions for the treatment of fibrosis. The present disclosure is directed to methods of tre...
Invention Compositions and methods for the treatment of metabolic and liver disorders
Invention Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders
Invention Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders. Discl...
Invention Thyroid beta-agonist dosing regimens for the treatment of x-ald. The present disclosure relates t...
Invention Oral dosage forms of trβ agonist vk2809 for the treatment of liver disorders and methods of prepa...
Invention Polymorphic forms and methods of producing polymorphic forms of a compound. Disclosed herein are...
Invention Oral dosage forms of tr.beta. agonist vk2809 for the treatment of liver disorders and methods of ...
Invention Polymorphic forms and methods of producing polymorphic forms of a compound. Disclosed herein are ...
Invention Pharmaceutical formulations and methods for the treatment of metabolic and liver disorders. Disc...
2022 Invention Compositions and methods for the treatment of metabolic and liver disorders. Disclosed herein ar...
Invention Use of thyroid beta-agonists. Methods useful for treating X-linked adrenoleukodystrophy are provi...
2021 Invention Compositions and methods for the treatment of liver disorders. The present disclosure is directe...
Invention Compositions and methods for the treatment of liver disorders. The present disclosure is directed...
2020 Invention Conjoint therapies with inhibitors of glucose production. The present invention provides pharmac...
2019 Invention Compositions for the treatment of fibrosis and inflammation. The present disclosure is directed t...
2018 Invention Compositions for the treatment of fibrosis. The present disclosure is directed to methods of trea...
Invention Compositions for the treatment of fibrosis. The present disclosure is directed to methods o...
2017 Invention Method of treating glycogen storage disease. The present disclosure provides methods and composit...
Invention Method of reducing thyroid-associated side effects. The present disclosure is directed to method...
Invention Compound for use in treating non-alcoholic fatty liver disease in a subject. The present disclosu...
Invention Method of reducing thyroid-associated side effects. The present disclosure is directed to methods...
Invention Use of thyroid beta-agonists. Methods useful for treating X-linked adrenoleukodystrophy are prov...
2015 P/S Research on orphan diseases and metabolic and endocrine disorders; research and development of bi...